factor

(redirected from Fibroblast growth factor)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.
Related to Fibroblast growth factor: Epidermal growth factor, Basic fibroblast growth factor

Factor

A financial institution that buys a firm's accounts receivable and collects the accounts.

Factor

A third party that buys a firm's accounts receivable. If a firm is not confident in its ability to collect on its credit sales, it may sell the right to receive payment to the factor at a discount. The factor then assumes the credit risk associated with the accounts receivable. This provides the firm immediate access to working capital, which is important, especially if the firm has a cash flow problem. The price of factoring is determined by the creditworthiness of the firm's customer, not of the firm itself. It is also known as accounts receivable financing.

factor

A firm that purchases accounts receivable from another firm at a discount. The purchasing firm then attempts to collect the receivables.

factor

To sell accounts receivable to another party at a discount from face value. Thus, a firm in need of cash to pay down short-term debt may decide to factor its accounts receivable to another firm.

factor

  1. a firm that purchases TRADE DEBTS from client firms. See FACTORING.
  2. a firm that buys in bulk and performs a WHOLESALING function.
  3. an input (for example raw material, labour, capital) which is used to produce a good or provide a service.

factor

  1. 1a FACTOR INPUT that is used in production (see NATURAL RESOURCES, LABOUR, CAPITAL).
  2. a business that buys in bulk and performs a WHOLESALING function.
  3. a business that buys trade debts from client firms (at some agreed price below the nominal value of the debts) and then arranges to recover them for itself. See FACTOR MARKET, FACTORING.
References in periodicals archive ?
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.
Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver.
This is the first demonstration that a wide variety of tumors produced abnormally high levels of basic fibroblast growth factor," Folkman told SCIENCE NEWS.
Founded by world leaders in the field of regenerative medicine, ProChon is a privately-held biotechnology company focused on modulating the fibroblast growth factor system to enable it to create more effective solutions for tissue regeneration.
We are very encouraged by the clinical evidence already generated by ProChon and believe there is tremendous potential for the use of their proprietary fibroblast growth factor in the field of cartilage repair.
These data reflect the results of the application of the ArQule Kinase Inhibitor Platform (AKIP[TM]) to discover and optimize a series of small molecule inhibitors of fibroblast growth factor receptor (FGFR) that are not ATP-competitive and show potent anti-tumor activity in FGFR-driven cancer models.
The present Competitive Intelligence Report about FGF-R agonists and antagonists provides a competitor evaluation in the field of fibroblast growth factor receptor (FGF-R) or PDGF targeting molecules for wound healing, cardiac tissue repair, bone formation or treatment of cancer as of November 2009.
Suramin blocks a hormone called fibroblast growth factor, which prostate tumors make in large quantities and which stimulates further tumor growth.
facility to manufacture its proprietary fibroblast growth factor (FGF2v) variant in the United States.
Roger Guillemin and colleagues at the Salk Institute in San Diego will soom publish the amino acid sequence of one called fibroblast growth factor.
Nasdaq: ARQL) today announced that a presentation at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in Boston on November 16, 2009, will highlight the discovery of potent, small molecule inhibitors of fibroblast growth factor receptor (FGFR) through the application of its proprietary ArQule Kinase Inhibitor Platform (AKIP[TM]).
Additionally, data assessing Fibroblast Growth Factor Receptor-2 (FGFR-2) response to an FGFR antagonist in a novel FGFR-2 driven model were also highlighted.